These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20505339)

  • 21. Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes.
    Alshawli AS; Wurdak H; Wood IC; Ladbury JE
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1429. PubMed ID: 32720471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth.
    Di Magno L; Manzi D; D'Amico D; Coni S; Macone A; Infante P; Di Marcotullio L; De Smaele E; Ferretti E; Screpanti I; Agostinelli E; Gulino A; Canettieri G
    Cell Cycle; 2014; 13(21):3404-13. PubMed ID: 25485584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cynanbungeigenin C and D, a pair of novel epimers from Cynanchum bungei, suppress hedgehog pathway-dependent medulloblastoma by blocking signaling at the level of Gli.
    Li XY; Zhou LF; Gao LJ; Wei Y; Xu SF; Chen FY; Huang WJ; Tan WF; Ye YP
    Cancer Lett; 2018 Apr; 420():195-207. PubMed ID: 29425683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli.
    Eberhart CG
    Am J Pathol; 2003 Jan; 162(1):7-10. PubMed ID: 12507884
    [No Abstract]   [Full Text] [Related]  

  • 25. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors.
    Grozinger CM; Schreiber SL
    Chem Biol; 2002 Jan; 9(1):3-16. PubMed ID: 11841934
    [No Abstract]   [Full Text] [Related]  

  • 26. Development of vorinostat: current applications and future perspectives for cancer therapy.
    Richon VM; Garcia-Vargas J; Hardwick JS
    Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas.
    Schüller U; Koch A; Hartmann W; Garrè ML; Goodyer CG; Cama A; Sörensen N; Wiestler OD; Pietsch T
    Int J Cancer; 2005 Oct; 117(1):82-9. PubMed ID: 15880586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitors in the treatment of hematological malignancies.
    Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
    Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of Histone Deacetylases Attenuate Noise-Induced Hearing Loss.
    Chen J; Hill K; Sha SH
    J Assoc Res Otolaryngol; 2016 Aug; 17(4):289-302. PubMed ID: 27095478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDAC2 deficiency and histone acetylation.
    Ree AH; Folkvord S; Flatmark K
    Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
    [No Abstract]   [Full Text] [Related]  

  • 33. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.
    Imai S; Armstrong CM; Kaeberlein M; Guarente L
    Nature; 2000 Feb; 403(6771):795-800. PubMed ID: 10693811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medulloblastoma growth inhibition by hedgehog pathway blockade.
    Berman DM; Karhadkar SS; Hallahan AR; Pritchard JI; Eberhart CG; Watkins DN; Chen JK; Cooper MK; Taipale J; Olson JM; Beachy PA
    Science; 2002 Aug; 297(5586):1559-61. PubMed ID: 12202832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics.
    Srivastava VK; Nalbantoglu J
    Cancer Biol Ther; 2010 Jun; 9(11):843-52. PubMed ID: 20372085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A BCL6/BCOR/SIRT1 complex triggers neurogenesis and suppresses medulloblastoma by repressing Sonic Hedgehog signaling.
    Tiberi L; Bonnefont J; van den Ameele J; Le Bon SD; Herpoel A; Bilheu A; Baron BW; Vanderhaeghen P
    Cancer Cell; 2014 Dec; 26(6):797-812. PubMed ID: 25490446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New therapy for medulloblastoma tested in mice.
    Wildasin K
    Lancet Neurol; 2004 Nov; 3(11):640. PubMed ID: 15515241
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecule of the month. Vorinostat.
    Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
    [No Abstract]   [Full Text] [Related]  

  • 39. A cyclodextrin-capped histone deacetylase inhibitor.
    Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
    Zirlik K; Nashan D; Veelken H
    Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.